Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 5/20 | 0.39 |
| ▸ | CDK8 | P49336 | 5/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088386 | 0.89 | MAP4K4 (0.44) | MKNK1MKNK2MAP4K4CCNCCDK8 | |
| SCHEMBL3761234 | 0.78 | GPR55 (0.56) | GPR55MKNK1MKNK2FLT3SMN1; SMN2 | |
| SCHEMBL3068540 | 0.75 | ESR1 (0.49) | SMN1; SMN2 | |
| SCHEMBL6533645 | 0.75 | HTR2A (0.39) | SMN1; SMN2 | |
| SCHEMBL3082420 | 0.74 | LPL (0.38) | — | |
| SCHEMBL4620312 | 0.74 | ESR1 (0.38) | SMN1; SMN2 | |
| SCHEMBL3074106 | 0.73 | BCL2L1 (0.49) | MAP4K4SMN1; SMN2 | |
| SCHEMBL3133913 | 0.73 | ESR1 (0.34) | — | |
| SCHEMBL3069374 | 0.71 | LPL (0.39) | FLT3PIK3CA | |
| SCHEMBL3072806 | 0.71 | BRD4 (0.48) | GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | claimed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | claimed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | claimed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | FANG JING | 2010-10-14 | — | — | US | disclosed |
| EP-1891026-B1 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723393-B2 | Cycloalkylidene compounds as selective estrogen receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | SMITHKLINE BEECHAM CORPORATION | 2008-07-10 | — | — | US | disclosed |
| EP-1891026-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | Smithkline Beecham Corporation (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006127871-A2 | CYCLOALKYLIDENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261772-A1 | Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | GPR55 96/4885MKNK1 2763/4885MKNK2 2757/4885 |
| US-20080167360-A1 | Cycloalkylidene Compounds as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | GPR55 96/4885MKNK1 2763/4885MKNK2 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.